Skip to main content
SpringerLink
Log in

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose: Therapy for high-grade gliomas remains unsatisfactory. Paclitaxel and topotecan have separately demonstrated activity against gliomas. We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.Patients and Methods: Adult patients with radiographic evidence of recurrent or progressive tumor following primary therapy were eligible for study. Patients received paclitaxel 175 mg/m2 IV over 3 h on day 1 and topotecan 1.0 mg/m 2 IV over 30 min on days 1–5. Filgrastim 5 μg/kg was given days 6–14 for neutrophil support. Treatment cycles were repeated every 21 days.Results: Twenty patients were enrolled on study, and seventeen were considered evaluable for response. Two patients (12/%) exhibited partial remission and seven patients (41/%) exhibited stable disease in response to therapy. Hematologic toxicity was common with 25 /% of patients experiencing grade III or IV leukopenia despite G-CSF support. Two patients died of infectious complications on protocol, prompting suspension of further accrual.Conclusion: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma. The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Fine HA Dear KB Loeffler JS et al. (1993) ArticleTitleMeta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 2585–2597

    Google Scholar 

  • MC Chamberlain P Kormanik (1995) ArticleTitleSalvage chemotherapy with paclitaxel for recurrent primary brain tumors J Clin Oncol 13 2066–2071

    Google Scholar 

  • BK Sinha (1995) ArticleTitleTopoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49 11–19

    Google Scholar 

  • HA Burris Suffix3rd AR Hanauske RK. Johnson et al. (1992) ArticleTitleActivity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro J Natl Cancer Inst 84 1816–1820

    Google Scholar 

  • B Arun EP Frenkel (2001) ArticleTitleTopoisomerase I inhibition with topotecan: pharmacologic and clinical issues Expert Opin Pharmacother 2 491–505

    Google Scholar 

  • C Sung SM Blaney DE Cole et al. (1994) ArticleTitleA pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid Cancer Res 54 5118–5122

    Google Scholar 

  • SM Blaney DE Cole FM Balis et al. (1993) ArticleTitlePlasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates Cancer Res 53 725–727

    Google Scholar 

  • HS Friedman PJ Houghton SC Schold et al. (1994) ArticleTitleActivity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Cancer Chemother Pharmacol 34 171–174

    Google Scholar 

  • CB Pratt C Stewart VM Santana et al. (1994) ArticleTitlePhase I study of topotecan for pediatric patients with malignant solid tumors J Clin Oncol 12 539–543

    Google Scholar 

  • HR Bahadori MR Green CV Catapano (2001) ArticleTitleSynergistic interaction between topotecan and microtubule-interfering agents Cancer Chemother Pharmacol 48 188–196

    Google Scholar 

  • TC Chou RJ Motzer Y Tong et al. (1994) ArticleTitleComputerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 86 1517–1524

    Google Scholar 

  • M Gore W ten Bokkel Huinink J Carmichael et al. (2001) ArticleTitleClinical evidence for topotecan-paclitaxel non–cross-resistance in ovarian cancer J Clin Oncol 19 1893–1900

    Google Scholar 

  • RC Lilenbaum MJ Ratain AA Miller et al. (1995) ArticleTitlePhase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study J Clin Oncol 13 2230–2237

    Google Scholar 

  • AA Miller RC Lilenbaum TJ Lynch et al. (1996) ArticleTitleTreatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel J Clin Oncol 14 1964–1965

    Google Scholar 

  • DR Macdonald TL Cascino SC Schold SuffixJr. et al. (1990) ArticleTitleResponse criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277–1280

    Google Scholar 

  • C Jennison BW Turnbull (1993) ArticleTitleGroup sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints Biometrics 49 741–752

    Google Scholar 

  • G Cairncross D Macdonald S Ludwin et al. (1994) ArticleTitleChemotherapy for anaplastic oligodendroglioma National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12 2013–2021 Occurrence Handle1:STN:280:ByqD3Mnos1c%3D Occurrence Handle7931469

    CAS  PubMed  Google Scholar 

  • CJ Langer J Ruffer H Rhodes et al. (2001) ArticleTitlePhase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme Int J Radiat Oncol Biol Phys 51 113–119

    Google Scholar 

  • SM Chang JG Kuhn HI Robins et al. (2001) ArticleTitleA Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report Cancer 91 417–422

    Google Scholar 

  • MR Fetell SA Grossman JD Fisher et al. (1997) ArticleTitlePreirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15 3121–3128

    Google Scholar 

  • D Macdonald G Cairncross D Stewart et al. (1996) ArticleTitlePhase II study of topotecan in patients with recurrent malignant glioma National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7 205–207

    Google Scholar 

  • B Fisher M Won D Macdonald et al. (2002) ArticleTitlePhase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513 Int J Radiat Oncol Biol Phys 53 980–986 Occurrence Handle10.1016/S0360-3016(02)02817-1 Occurrence Handle1:CAS:528:DC%2BD38XkvFyrtr4%3D Occurrence Handle12095566

    Article  CAS  PubMed  Google Scholar 

  • GF Fleming JW Kugler PC Hoffman et al. (1998) ArticleTitlePhase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer J Clin Oncol 16 2032–2037

    Google Scholar 

  • W West R Birch F Schnell et al. (2003) ArticleTitlePhase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer Oncologist 8 76–82

    Google Scholar 

  • SM Chang JG Kuhn J Rizzo et al. (1998) ArticleTitlePhase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report J Clin Oncol 16 2188–2194

    Google Scholar 

  • MJ Glantz H Choy CM Kearns et al. (1996) ArticleTitlePhase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas J Clin Oncol 14 600–609

    Google Scholar 

  • A Younes HA Preti FB Hagemeister et al. (2001) ArticleTitlePaclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma Ann Oncol 12 923–927

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-Oncology Program, Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, 1 Medical Center Drive, New Hampshire, Lebanon, NH, USA, 03756

    J. Marc Pipas, Louise P. Meyer, C. Harker Rhodes, Laurence D. Cromwell, Carol E. McDonnell, Linda S. Kingman , James R. Rigas & Camilo E. Fadul

Authors
  1. J. Marc Pipas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louise P. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Harker Rhodes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurence D. Cromwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carol E. McDonnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Linda S. Kingman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James R. Rigas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Camilo E. Fadul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Marc Pipas.

Additional information

Supported with grant funding from: GlaxoSmithKline Pharmaceuticals Collegeville, PA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pipas, J.M., Meyer, L.P., Rhodes, C.H. et al. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71, 301–305 (2005). https://doi.org/10.1007/s11060-004-2026-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-004-2026-2

Keywords

Search

Navigation